Fig. 4.

Prophylactic treatment with mitazalimab and OVA protein prolongs the survival of E.G7-OVA tumor-bearing mice and induces immunological memory against OVA—Naïve hCD40tg mice were immunized twice with 200 µg OVA protein or PBS control i.v., 7 days between. Mitazalimab or Ctr IgG (100 µg) were given i.p. either every 2–3 days or every 7 days during a 12-day period, starting from the first OVA injection. On day 14, 1 × 10⁶ E.G7-OVA cells were inoculated s.c. a Overview of the experimental setup, b E.G7-OVA tumor growth throughout the study. Tumor growth is displayed until the point where the first mouse in each group approaches the ethical tumor volume limit of 2 cm³ and is sacrificed, c frequency of survival throughout the study. Pooled data from two identical experiments are shown in b and c. The complete responders in c were again inoculated with 1 × 10⁶ E.G7-OVA cells s.c. on one flank and 1 × 10⁶ EL-4 cells on the other flank, d E.G7-OVA and EL-4 tumor growth of the complete responders. Tumor growth is displayed until the point where the first complete responder is sacrificed. n = 8–10 per group, per experiment, in a–c; n = 5 in total in d. Statistical significance was analyzed by the log-rank test in c. All error bars indicate ± SEM